ストックスクリーナーアプリを入手
0.00
100.00%
-0.0549
前日終値:
$0.0549
開ける：
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額：
$14.55M
収益：
$175.04M
当期純損益:
$-44.52M
株価収益率:
0.00
EPS:
-0.18
ネットキャッシュフロー:
$-56.05M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$0.00
$0.00
52週間の値動き範囲:
$0.00
$0.8334
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
名前
Adaptimmune Therapeutics Plc Adr
セクター
電話
44 1235 430000
住所
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
ADAP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.00 | 14.55M | 175.04M | -44.52M | -56.05M | -0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-06-26 | ダウングレード | Mizuho | Outperform → Neutral |
| 2024-07-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-30 | 開始されました | Scotiabank | Sector Outperform |
| 2023-03-24 | 開始されました | Bryan Garnier | Buy |
| 2023-01-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-11-09 | アップグレード | Mizuho | Neutral → Buy |
| 2021-05-28 | 開始されました | Barclays | Underweight |
| 2020-04-22 | 開始されました | Mizuho | Neutral |
| 2019-08-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-05-31 | 開始されました | ROTH Capital | Buy |
| 2019-05-30 | 再開されました | Citigroup | Buy |
| 2019-05-07 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2017-03-17 | 開始されました | Wells Fargo | Market Perform |
| 2016-10-24 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2016-09-30 | 開始されました | Raymond James | Outperform |
| 2016-02-25 | 開始されました | Citigroup | Buy |
| 2015-06-01 | 開始されました | BofA/Merrill | Neutral |
| 2015-06-01 | 開始されました | Guggenheim | Buy |
| 2015-06-01 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Adaptimmune Therapeutics Plc Adr (ADAP) 最新ニュース
How Adaptimmune Therapeutics plc (Common Stock) (473A) stock performs during market turbulence2025 EndofYear Setup & Technical Pattern Based Signals - newser.com
Adaptimmune Therapeutics PLC (ADAPY) Stock PDF (Updated: 2025/11/05) - GuruFocus
Adaptimmune Therapeutics PLC Sponsored ADR Financial Disclosures & SEC Filings - TradingView
Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback? - ts2.tech
Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer - GlobeNewswire Inc.
Why Crown Holdings Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Adaptimmune stock plunges after announcing Nasdaq delisting plans By Investing.com - Investing.com Philippines
Adaptimmune stock plunges after announcing Nasdaq delisting plans - Investing.com India
Adaptimmune to delist from Nasdaq amid cost-cutting efforts - Investing.com
Pre-Market Movers: MIRA, ADAP, GNPX Swing Big - RTTNews
Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp? - ts2.tech
Pre-Market Titans: TTRX, BJDX & UPC Set The Pace - RTTNews
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real? - ts2.tech
Morning Market Movers: FEMY, PALI, COSM, Seeing Big Swings - RTTNews
Adaptimmune Granted Exception Period by Nasdaq Panel - The Globe and Mail
Morning Market Movers: MRM, LEXX, WOLF See Big Swings - RTTNews
Stocks Moving Premarket: PEPG, WOK, ICU, And Other Gainers & Losers - RTTNews
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC - Yahoo Finance
Must-Watch Streaming Stocks Poised to Gain From Content Boom - Yahoo Finance
Is Hesai Group Sponsored ADR (HSAI) Outperforming Other Auto-Tires-Trucks Stocks This Year? - Yahoo Finance
Lenovo Finds 65% of IT Leaders Admit Their Defenses Can’t Withstand AI Cybercrime - Yahoo Finance
Why the Market Dipped But Li Auto Inc. Sponsored ADR (LI) Gained Today - Yahoo Finance
What Does Wall Street Think About Li Auto Inc. (LI)? - Yahoo Finance
Vestas Wind Systems AS ADR (VWDRY) Wind Turbines Orders on the Rise - Yahoo Finance
The Zacks Analyst Blog Highlights Walmart, Alibaba, Shell, Omega Flex and Weyco - Yahoo Finance
Investors Take Advantage Of 15.76% Gain In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - stocksregister.com
What Is Going On With Top KingWin Ltd (NASDAQ: WAI)? - stocksregister.com
Rio Tinto plc ADR Common Stock (RIO) Restructures to Focus on Profitable Assets - Yahoo Finance
Zacks.com featured highlights include Halozyme Therapeutics, Phibro, Leidos and PDD Holdings - Yahoo Finance
Adaptimmune Therapeutics CFO Wood sells $950 in shares - Investing.com
Nio Inc. ADR (NIO) Upgraded to ‘Overweight’ at JPMorgan on Strong Vehicle Demand - Yahoo Finance
Earnings call transcript: Adaptimmune Q2 2025 shows revenue beat, stock dips - Investing.com
Adaptimmune director Behbahani sells shares worth $229,171 - Investing.com
Are Investors Undervaluing ENGIESponsored ADR (ENGIY) Right Now? - Yahoo Finance
Adaptimmune Faces Nasdaq Delisting Notice Amid Compliance Issues - MSN
Adaptimmune Sales Jump 59 Percent - sharewise.com
Is Piedmont Lithium Inc.Sponsored ADR (PLL) Stock Outpacing Its Basic Materials Peers This Year? - Yahoo Finance
ADAP’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - Yahoo Finance
Wall Street Today: Dow, Nasdaq, S&P 500 open higher as investors focus on optimism over potential US Fed rate cut - Mint
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Ecor1 capital sells Adaptimmune Therapeutics (ADAP) shares for $6.89m - Investing.com India
Adaptimmune stock rating downgraded by H.C. Wainwright after asset sale - Investing.com South Africa
Adaptimmune Therapeutics stock plunges after selling cell therapy assets By Investing.com - Investing.com India
Adaptimmune Therapeutics stock plunges after selling cell therapy assets - Investing.com
Adaptimmune sells cell therapy assets to US WorldMeds for $55 million - Investing.com
XPeng Inc. Sponsored ADR (XPEV) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect - Yahoo Finance
Mizuho downgrades Adaptimmune stock on solvency concerns - Investing.com
Financial Metrics Unveiled: MARA Holdings Inc (MARA)’s Key Ratios in the Spotlight - DWinneX
Best Momentum Stocks to Buy for June 12th - Yahoo Finance
Adaptimmune Therapeutics Plc Adr (ADAP) 財務データ
収益
当期純利益
現金流量
EPS
5.44%
0.70%
大文字化:
|
ボリューム (24 時間):